DK1664319T3 - Fremgangsmåde til fremstilling af et kapsel-polysaccharid til anvendelse i konjugatvacciner - Google Patents

Fremgangsmåde til fremstilling af et kapsel-polysaccharid til anvendelse i konjugatvacciner

Info

Publication number
DK1664319T3
DK1664319T3 DK04774932.0T DK04774932T DK1664319T3 DK 1664319 T3 DK1664319 T3 DK 1664319T3 DK 04774932 T DK04774932 T DK 04774932T DK 1664319 T3 DK1664319 T3 DK 1664319T3
Authority
DK
Denmark
Prior art keywords
polysaccharide
preparation
conjugate vaccines
capsule polysaccharide
base
Prior art date
Application number
DK04774932.0T
Other languages
English (en)
Inventor
Michel Francois Beurret
Ahd Hamidi
Original Assignee
Staat Der Nederlanden Vert Doo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Staat Der Nederlanden Vert Doo filed Critical Staat Der Nederlanden Vert Doo
Application granted granted Critical
Publication of DK1664319T3 publication Critical patent/DK1664319T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/102Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK04774932.0T 2003-09-11 2004-09-10 Fremgangsmåde til fremstilling af et kapsel-polysaccharid til anvendelse i konjugatvacciner DK1664319T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03077881 2003-09-11
PCT/NL2004/000627 WO2005024038A2 (en) 2003-09-11 2004-09-10 Process for producing a capsular polysaccharide for use in conjugate vaccines

Publications (1)

Publication Number Publication Date
DK1664319T3 true DK1664319T3 (da) 2010-05-10

Family

ID=34259185

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04774932.0T DK1664319T3 (da) 2003-09-11 2004-09-10 Fremgangsmåde til fremstilling af et kapsel-polysaccharid til anvendelse i konjugatvacciner

Country Status (12)

Country Link
US (1) US7582459B2 (da)
EP (1) EP1664319B1 (da)
KR (1) KR101161033B1 (da)
AT (1) ATE460498T1 (da)
CA (1) CA2538691C (da)
DE (1) DE602004025951D1 (da)
DK (1) DK1664319T3 (da)
ES (1) ES2341863T3 (da)
PL (1) PL1664319T3 (da)
PT (1) PT1664319E (da)
SI (1) SI1664319T1 (da)
WO (1) WO2005024038A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
ATE548051T1 (de) 2005-04-08 2012-03-15 Wyeth Llc Multivalente pneumokokken- polysaccharidproteinkonjugatzusammensetzung
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0522303D0 (en) * 2005-11-01 2005-12-07 Chiron Srl Culture method
GB0605757D0 (en) * 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
KR101045881B1 (ko) * 2008-09-11 2011-07-01 전남대학교산학협력단 연쇄상구균으로부터의 협막다당 생산 배지, 생산 방법 및 정제 방법
HUE046859T2 (hu) * 2008-12-18 2020-03-30 Wyeth Llc Eljárás Streptococcus pneumoniae poliszacharid molekulatömegének szabályozására szén alkalmazásával
ES2666698T3 (es) * 2008-12-18 2018-05-07 Wyeth Llc Procedimiento de control del peso molecular del polisacárido del serotipo 19A de Streptococcus pneumoniae
DE102009022251A1 (de) * 2009-05-20 2010-11-25 Technische Universität Bergakademie Freiberg Verfahren und Mittel zur extraktiven Gewinnung organischer Substanzen
SG10201407096RA (en) * 2009-10-30 2014-12-30 Novartis Ag Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011148382A1 (en) * 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
CN102175841A (zh) * 2010-12-30 2011-09-07 北京民海生物科技有限公司 一种脑膜炎球菌多糖结合物中游离多糖含量的测定方法
CN104080904B (zh) * 2011-12-15 2017-06-30 血清研究所印度私人有限公司 培养细菌以提高荚膜多糖产率的新方法
CN102628068B (zh) * 2012-04-23 2013-09-04 成都欧林生物科技股份有限公司 b型流感嗜血杆菌高密度培养生产细菌荚膜多糖的方法
WO2014009971A2 (en) 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
ES2933127T3 (es) * 2012-12-20 2023-02-01 Pfizer Procedimiento de glucoconjugación
MY186874A (en) * 2014-02-25 2021-08-26 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd A novel downstream process for purifying polysaccharides
KR102388325B1 (ko) 2016-10-20 2022-04-18 케이엠 바이올로직스 가부시키가이샤 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법
KR102028693B1 (ko) * 2017-04-27 2019-10-04 주식회사 유바이오로직스 스트렙토코커스 뉴모니아 협막 다당체의 생산방법
RU2704452C1 (ru) * 2019-04-22 2019-10-28 Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства Способ получения вакцины гемофильной тип b конъюгированной

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US5316926A (en) * 1983-11-25 1994-05-31 Miles Inc. Method for the microbiological production of non-antigenic hyaluronic acid
US5192540A (en) 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
GB9024223D0 (en) * 1990-11-07 1990-12-19 Fermentech Ltd Production of hyaluronic acid
US6410025B1 (en) * 1996-02-14 2002-06-25 Merck & Co., Inc. Polysaccharide precipitation process
DE59812033D1 (de) * 1997-01-24 2004-11-04 Schweiz Serum & Impfinst Neues verfahren zur isolierung von polysacchariden

Also Published As

Publication number Publication date
CA2538691C (en) 2014-01-14
WO2005024038A2 (en) 2005-03-17
KR20060092234A (ko) 2006-08-22
SI1664319T1 (sl) 2010-06-30
EP1664319B1 (en) 2010-03-10
PT1664319E (pt) 2010-06-17
ES2341863T3 (es) 2010-06-29
CA2538691A1 (en) 2005-03-17
EP1664319A2 (en) 2006-06-07
US7582459B2 (en) 2009-09-01
KR101161033B1 (ko) 2012-06-28
ATE460498T1 (de) 2010-03-15
WO2005024038A3 (en) 2005-12-29
DE602004025951D1 (de) 2010-04-22
US20070065460A1 (en) 2007-03-22
PL1664319T3 (pl) 2010-07-30

Similar Documents

Publication Publication Date Title
DK1664319T3 (da) Fremgangsmåde til fremstilling af et kapsel-polysaccharid til anvendelse i konjugatvacciner
HK1108713A1 (en) Animal protein free media for cultivation of cells
MX2019002495A (es) Metodos para producir virus para la produccion de vacunas.
BRPI0507347A (pt) métodos de produção de l-treonina e de microrganismo produtor de l-treonina e microrganismo
NO20053357L (no) Dyrkingsmedium, dyrkingsmetode og de oppnadde myoblaster og deres anvendelse.
DK1651758T3 (da) Fremgangsmåde tl fremstilling af L-lysin eller L-threonin ved anvendelse af Escherichia bakterier med svækket æblesyreenzymaktivitet
DK0983342T3 (da) Dyrkningsmedium med sojabönneekstrakt som aminosyrekilde og ingen proteinkomplekser af dyreoprindelse
WO2004001007A3 (en) Buffered formulations for concentrating antibodies and methods of use thereof
ATE418954T1 (de) Verfahren zum herstellen eines einsatzes
DE69533964D1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
DK1067911T3 (da) Hydrogelsammensætninger, der kan anvendes til opretholdt frigivelse af makromolekyler, samt fremgansmåder tilfremstilling deraf
DK1689461T5 (da) Anvendelse af en hydrogel til dyrkning af chondrocytter
NO20053328L (no) Immunisering av fisk med uttrykte proteiner i planteceller.
ATE440605T1 (de) Verfahren zur herstellung von camptothecin- derivaten
ATE526034T1 (de) Verbesserte inaktivierte fcv-vakzinen
DK1608388T3 (da) Fremgangsmåde til fremstilling af en ekstrakt af efeublade
AR052142A1 (es) Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
TR200606983T1 (tr) Nodavirüs-VLP bağışıklaştırma bileşimi
NO20083269L (no) Prosess for a anvende krystallinsk orlistatmetoder
DK1509244T3 (da) Ny fremgangsmåde og præparat til at producere en cellulær allogen vaccine
SE9903534D0 (sv) Vaccin
DK1438057T3 (da) Fyrrekogleekstrakter og anvendelser deraf
EP1591520A3 (en) Microorganism producing L-threonine having inactivated tyR gene, method of producing the same and method of producing L-threonine using the microorganism
ATE325174T1 (de) Verfahren zur herstellung von photolumineszenten polarisatoren